Teva receives approval for Azithromycin tablets

New York, Nov. 14 - Teva Pharmaceutical Industries Ltd. said that the U. S. Food and Drug Administration granted final approval for its ANDAs for Azithromycin tablets, 250 mg, 500 mg and 600 mg.

Azithromycin is the AB-rated generic equivalent of Pfizer's antibiotic Zithromax tablets with annual sales of $1.6 billion.

Teva said it is currently in patent litigation concerning the product in the U.S. District Court for the Southern District of New York.

Teva is a Jerusalem, Israel-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.